CD33 and myelodysplastic syndrome: Researchers found that BI 836858 reduces the number of MDSCs derived from MDS patients through antibody-dependent cellular cytotoxicity (ADCC) and blocks downstream signaling of CD33, resulting in reduced expressions of IL-10 and ROS, genomic stability, and improving the hematopoiesis in low-risk MDS bone marrow specimens ex vivo [132].